Form 4: Beta Bionics Director Sells Shares Under 10b5-1 Plan

Beta Bionics Director Adam Lezack sold 1,406 shares of common stock on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Adam Lezack, a Director of Beta Bionics, Inc. (BBNX), reported the sale of common stock.
• On December 1, 2025, Lezack sold 906 shares at a weighted average price of $29.3463 per share, with prices ranging from $28.75 to $29.63.
• On the same date, Lezack sold an additional 500 shares at a weighted average price of $29.91 per share, with prices ranging from $29.80 to $30.16.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025.
• Following these transactions, Adam Lezack beneficially owns 8,435 shares of Beta Bionics common stock directly.

Sentiment

Score: 4

Explanation: The sale of shares by a director is generally viewed as a negative signal, but the pre-arranged nature under a 10b5-1 plan reduces the immediate concern that it's based on new, adverse information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating the transactions were scheduled in advance and not necessarily based on new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence or a desire to diversify holdings.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This filing is a routine insider transaction report and does not provide information for broader industry trend analysis.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, potentially influencing short-term sentiment.

Key Dates

Recommendation

While insider selling can be a negative signal, the transaction was executed under a pre-established 10b5-1 plan, suggesting it was not based on new, material non-public information. This single transaction does not provide sufficient new information to alter a fundamental investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Beta Bionics, BBNX, Form 4, insider trading, stock sale, director, 10b5-1 plan